BSE filing, NSE: INDOUS. Summary written from the filing by ALFA Finder's alert engine.
Indo US Bio-Tech Ltd: key numbers
- Share price
- ₹86.84
- Market cap
- ₹174.1 Cr
- Revenue (annual)
- ₹110.4 Cr
- Net profit (annual)
- ₹13.12 Cr
- P/E (TTM)
- 15.2×Sector 26.2×
- Promoter holding
- 68.29%+0.00% QoQ
- FII holding
- 0.01%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Indo US Bio-Tech Ltd
All →Indo US Bio-Tech Board Meeting Date
Indo Us Bio-Tech has intimated that its board will meet on 30 October 2026 to consider unaudited standalone results for the quarter and half year ended 30 September 2026. The notice is advance intimation only, with no results yet reported.
Indo US Bio-Tech Business Update
Indo Us Bio-Tech disclosed promoter invitations to attend China's 140th Canton Fair. The filing states no financial value or business commitment.
Indo US Bio-Tech Annual General Meeting
Indo Us Bio-Tech Limited held its 22nd Annual General Meeting on September 30, 2026. The filing provides a gist of the meeting's proceedings and agenda items.
Indo US Bio-Tech Annual Report
Indo Us Bio-Tech Ltd submitted its Annual Report for FY 2025-2026. The 22nd Annual General Meeting is scheduled for September 30, 2026.
Indo US Bio-Tech Annual General Meeting
Indo Us Bio-Tech Limited has issued a notice for its 22nd Annual General Meeting, scheduled for September 30, 2026, to be conducted via video conferencing.
Indo US Bio-Tech Board Meeting Outcome
Indo Us Bio-Tech Ltd announced outcomes of its board meeting, including the date for its 22nd AGM and appointment of statutory auditors.
Other other announcement announcements
All →Mahindra & Mahindra Financial Services Other Announcement
Mahindra & Mahindra Financial filed its ALM statement as of September 30, 2026, submitted to RBI. It is a periodic regulatory return with no new transaction.
ACME Solar Holdings Other Announcement
ACME Solar filed the CARE Ratings monitoring agency report on its Rs.2,800 crore QIP for the quarter ended 30 September 2026. The report shows no deviation from the offer objects.
eMudhra Other Announcement
eMudhra Ltd disclosed that SES ESG revised its ESG score from 68.0 to 64.9 in its ESG Report 2026. The company states it did not engage SES ESG, and the revision relates to its certificate business.
Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.